Tracking Early Markers of Progression in Neurodegenerative Diseases
Follows people with neurodegenerative diseases, such as Parkinson disease, through routine checkups over time.
Key facts
- Who runs it
- Casa di Cura San Raffaele Cassino
- Where
- Cassino, ItalySee the site
- Trial code
- Registry title
- Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
- Status
- Recruiting
- People taking part
- 600 people, planned
- Started
- 9 Sept 2024
- Expected to end
- 9 Sept 2034
- Type of study
- Observational, 2 groups
- Treatments tested
- Observation
- Record updated
- 2 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with Parkinson's disease, other movement disorders, or memory and thinking problems such as dementia. They are followed over time during their normal clinic visits.
- Age
- From 10 years. No upper age limit is stated, and the record says there are no age restrictions.
- Sex
- All sexes can join.
- Disease stage
- Parkinson's disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Essential Tremor, Lewy Body Dementia, Alzheimer's Disease, mild cognitive decline, or subjective memory complaints. Any severity can join.
Main reasons for not taking part
- People who cannot complete the research assessments cannot join.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders; Patients with diagnosis of Parkinson's Disease; Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank; Diagnosis of Movement Disorder not related to Parkinson's Disease; Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy; Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy; Diagnosis of Essential Tremor; Willing to participate in the study, understand the procedures and sign the informed consent
- Patients affected by cognitive impairment (CI) and dementia; Diagnosis of probable:; Lewy Body Dementia; Alzheimer's Disease; Mild Cognitive Decline; Subjective memory complaints; Willing to participate in the study, understand the procedures and sign the informed consent
Who cannot take part
- There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments
Where in Italy
- San Raffaele CassinoCassino, ItalyContact: Maria Francesca De Pandis, MD, PhDTaking people
About the trial
What the trial wants to find out
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.
The 2 groups in the trial
- Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders
Treatment: Observation
- Patients affected by cognitive impairment (CI) and dementia
Treatment: Observation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
- Plain-language title
- Tracking Early Markers of Progression in Neurodegenerative DiseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 September 2026